US 11,980,618 B2
Nitric oxide releasing phosphodiesterase type 5 inhibitor
Nicoletta Almirante, Milan (IT); Stefania Brambilla, Merone (IT); Laura Storoni, Cesano Maderno (IT); Francesco Impagnatiello, Milan (IT); and Elena Bastia, Milan (IT)
Assigned to NICOX S.A., Valbonne (FR)
Appl. No. 17/265,134
Filed by NICOX S.A., Valbonne (FR)
PCT Filed Jul. 31, 2019, PCT No. PCT/EP2019/070597
§ 371(c)(1), (2) Date Feb. 1, 2021,
PCT Pub. No. WO2020/030489, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 18187482 (EP), filed on Aug. 6, 2018; and application No. 18210147 (EP), filed on Dec. 4, 2018.
Prior Publication US 2021/0322413 A1, Oct. 21, 2021
Int. Cl. A61K 31/506 (2006.01); A61K 31/197 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 27/06 (2006.01); C07D 403/14 (2006.01); C07D 487/04 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/197 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 27/06 (2018.01); C07D 403/14 (2013.01); C07D 487/04 (2013.01)] 14 Claims
 
1. A compound of formula (II) or a stereoisomer or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
R1 is a residue of a nitric oxide releasing molecule having a formula:
R1=—C(O)—(O—CH2)y(CH2)m—[O—(CH2)n]p—(CH—ONO2)q—CH2—ONO2
wherein:
y is 1 or 0;
p is 1 or 0;
q is 1 or 0;
m is an integer ranging from 1 to 10;
n is an integer ranging from 1 to 6.